Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Ethical Drug Market in Japan Grew 1.6% to ¥9,035,806 Mil. in FY2010: IMS Japan
July 4, 2011
- METI Advisory Committee Proposes Exclusion of OTC-like Drugs from Insurance Coverage
July 4, 2011
- Sprycel Approved as 1st-line Treatment for CML: Bristol-Myers, Otsuka
July 4, 2011
- Wakamoto Licenses Ophthalmic Surgical Adjuvant from Kyushu Univ. Bioventure
July 4, 2011
- PMDA to Give Priority to Regenerative Medicine, Cancer in Regulatory Strategy Consultation
July 4, 2011
- Number of Deaths Reached Post-war High in 2010: Korosho
July 4, 2011
- Astellas Transfers Luvox to Abbott Japan
July 4, 2011
- Korosho Asks Takeda to Revise Package Insert for Actos
July 4, 2011
- With Right Infrastructure, “Bright Future”for Multinational Trials: Mr Morimoto of CMIC
July 4, 2011
- Sosei Group to Collaborate with Gifu Pharm. Univ.
July 4, 2011
- Korosho Instructs Revision of Package Inserts for Pioglitazone
July 4, 2011
- Korosho to Select 5 Hub Med. Institutions for Early-stage Clinical Studies
July 4, 2011
- Tsuruha HD: Dispensing Fees Up 10.2% in FY2010
July 4, 2011
- EMA to Issue Conclusion on Bladder Cancer Risk from Actos in July
July 4, 2011
- Nycomed Takes Over Bisphosphonate from Roche
June 27, 2011
- Takeda to Start PIII Trial for Hib Vaccine
June 27, 2011
- Eiken: Sales Up 2.7% Driven by Extraordinary Demand due to Disaster
June 27, 2011
- NanoCarrier to Obtain Substance Patent for pH-Responsive Micelles
June 27, 2011
- Otsuka to Start PI for Cancer Vaccine OCV-105 in Japan
June 27, 2011
- Takara Bio: Sales Down 3.0% due to Decline in Sales of Scientific Instruments
June 27, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…